Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2005 2
2006 3
2007 1
2008 1
2009 1
2013 1
2014 1
2016 2
2017 2
2018 3
2019 5
2020 8
2021 10
2022 10
2023 7
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H. Wakita S, et al. Among authors: marumo a. Blood Adv. 2022 Jan 11;6(1):238-247. doi: 10.1182/bloodadvances.2021004292. Blood Adv. 2022. PMID: 34448807 Free PMC article.
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
Wakita S, Marumo A, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Arai H, Kanda M, Itabashi K, Fukuda T, Kanda Y, Yamaguchi H. Wakita S, et al. Among authors: marumo a. Cancer Sci. 2023 Apr;114(4):1297-1308. doi: 10.1111/cas.15720. Epub 2023 Jan 27. Cancer Sci. 2023. PMID: 36610002 Free PMC article.
Relapse of Acquired Hemophilia A after COVID-19 Infection.
Marumo A, Sugihara H, Omori I, Morishita E. Marumo A, et al. J Nippon Med Sch. 2024 Jan 20;90(6):474-479. doi: 10.1272/jnms.JNMS.2023_90-609. Epub 2023 Feb 21. J Nippon Med Sch. 2024. PMID: 36823120 Free article.
[A favorable clinical course of acute myeloid leukemia with t (6;21;8)(p23;q22;q22)].
Wada A, Doki N, Otsuka Y, Adachi H, Konuma R, Kishida Y, Konishi T, Yamada Y, Nagata A, Nagata R, Marumo A, Noguchi Y, Mukae J, Toya T, Igarashi A, Najima Y, Kobayashi T, Harada H, Harada Y, Sakamaki H, Ohashi K. Wada A, et al. Among authors: marumo a. Rinsho Ketsueki. 2022;63(2):104-107. doi: 10.11406/rinketsu.63.104. Rinsho Ketsueki. 2022. PMID: 35264498 Japanese.
An advanced case of gastric histiocytic sarcoma treated with chemotherapy and gastrectomy: a case report and review of literature.
Matsunaga R, Kanazawa Y, Matsuno K, Kakinuma D, Tokura T, Marumo A, Yui S, Ando F, Masuda Y, Hagiwara N, Nomura T, Kato S, Yoshiyuki T, Domoto Y, Sakatani T, Ohashi R, Inokuchi K, Yoshida H. Matsunaga R, et al. Among authors: marumo a. Clin J Gastroenterol. 2021 Aug;14(4):1053-1059. doi: 10.1007/s12328-021-01438-y. Epub 2021 Jun 8. Clin J Gastroenterol. 2021. PMID: 34100257 Review.
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
Marumo A, Wakita S, Morita K, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Uoshima N, Kobayashi Y, Kawata E, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Kubota Y, Kimura S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Date K, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Ohashi K, Kanda Y, Yamaguchi H. Marumo A, et al. Int J Hematol. 2022 Aug;116(2):199-214. doi: 10.1007/s12185-022-03328-6. Epub 2022 Apr 4. Int J Hematol. 2022. PMID: 35377134
Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y, Arai Y, Nishiwaki S, Mizuta S, Marumo A, Uchida N, Kanda Y, Sakai H, Takada S, Fukuda T, Fujisawa S, Ashida T, Tanaka J, Atsuta Y, Kako S. Akahoshi Y, et al. Among authors: marumo a. Int J Hematol. 2021 Jun;113(6):832-839. doi: 10.1007/s12185-021-03094-x. Epub 2021 Feb 11. Int J Hematol. 2021. PMID: 33570732 Clinical Trial.
50 results